Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (799)	12/23/1998 8:11:00 PM
From: Craig A	Respond to of 1686

Stop limit here?

To: William Partmann who wrote (799)	12/23/1998 11:21:00 PM
From: JEB	Respond to of 1686

Singular over reaction which will have straightened itself out by Monday of next week. The best of the shorts will want to cover by 1:00 tomorrow (End of trading day). BGEN will start climbing tomorrow and Monday.

To: William Partmann who wrote (799)	12/25/1998 1:02:00 PM
From: William Partmann	Read Replies (1) \| Respond to of 1686

A Christmas review: 1. Biogen Inc. (BGEN): The biotechnology company was raised to ''strong buy'' from ''outperform'' by analyst Douglas D. Lind at Morgan Stanley Dean Witter. Lind expects the stock price to rise to $90. Biogen fell 7 1/16 to 79 13/16. 2. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US) was maintained ''market outperform'' by analyst May-Kin Ho at Goldman, Sachs & Co. 3. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US) was rated ''buy'' in new coverage by analyst Jay B. Silverman at BancBoston Robertson Stephens. The 12-month target price is $100.00 per share. 4. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US) was maintained ''buy'' by analyst Meirav Chovav at Salomon Smith Barney. Chovav raised his price target to $92.00 from $80.00 per share. 5. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US) was maintained ''buy'' by analyst C. Anthony Butler at Lehman Brothers. The price target is $100.00 per share. 6. Princeton, New Jersey, Dec. 24 (Bloomberg Data) -- Biogen Inc. (BGEN US) was maintained ''buy'' by analyst Jeffrey R. Swarz at Credit Suisse First Boston Inc. The price target is $90.00 per share. 7. Hambrick and Quist also mainted Bgen at a buy. 8. Dec 24 (Reuters) - EVEREN Securities said Thursday it viewed the sell-off in shares of Biogen Inc. (Nasdaq:BGEN - news) as a buying opportunity and would be ''aggressively'' purchasing shares at current levels. -- Biogen shares fell sharply Wednesday after the surprise news that James Tobin would resign as chief executive officer. The stock closed at 79-13 on Nasdaq, down 7-1/16. It was down as much as 16-2/16 during the day. -- EVEREN says Biogen is a profitable biotechnology company that is marketing the leading treatment for multiple sclerosis, receives royalty revenues from four compounds, and has several promising products in clinical development. -- ''We view investors as overreacting to the news, as it blindsided everybody on the street, and would be aggressively buying shares,'' EVEREN said in a report. -- It has the stock rated outperform on both an intermediate and long-term basis 9. Merrill on Monday? I believe this bodes well for Monday. Merry Christmas everyone.